Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Enhanced gene delivery by avidin-displaying baculovirus.

Räty JK, Airenne KJ, Marttila AT, Marjomäki V, Hytönen VP, Lehtolainen P, Laitinen OH, Mähönen AJ, Kulomaa MS, Ylä-Herttuala S.

Mol Ther. 2004 Feb;9(2):282-91.

2.

(Strept)avidin-displaying lentiviruses as versatile tools for targeting and dual imaging of gene delivery.

Kaikkonen MU, Lesch HP, Pikkarainen J, Räty JK, Vuorio T, Huhtala T, Taavitsainen M, Laitinen T, Tuunanen P, Gröhn O, Närvänen A, Airenne KJ, Ylä-Herttuala S.

Gene Ther. 2009 Jul;16(7):894-904. doi: 10.1038/gt.2009.47. Epub 2009 May 14.

PMID:
19440224
3.

A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide.

Morizono K, Xie Y, Helguera G, Daniels TR, Lane TF, Penichet ML, Chen IS.

J Gene Med. 2009 Aug;11(8):655-63. doi: 10.1002/jgm.1345.

4.

Targeting of biotinylated compounds to its target tissue using a low-density lipoprotein receptor-avidin fusion protein.

Lehtolainen P, Wirth T, Taskinen AK, Lehenkari P, Leppänen O, Lappalainen M, Pulkkanen K, Marttila A, Marjomäki V, Airenne KJ, Horton M, Kulomaa MS, Ylä-Herttuala S.

Gene Ther. 2003 Dec;10(25):2090-7.

PMID:
14595382
5.

Development of adenovirus immobilization strategies for in situ gene therapy.

Hu WW, Lang MW, Krebsbach PH.

J Gene Med. 2008 Oct;10(10):1102-12. doi: 10.1002/jgm.1233.

6.
7.

Targeting and purification of metabolically biotinylated baculovirus.

Kaikkonen MU, Viholainen JI, Närvänen A, Ylä-Herttuala S, Airenne KJ.

Hum Gene Ther. 2008 Jun;19(6):589-600. doi: 10.1089/hum.2007.177.

PMID:
18479188
8.

Avidin fusion protein-expressing lentiviral vector for targeted drug delivery.

Lesch HP, Pikkarainen JT, Kaikkonen MU, Taavitsainen M, Samaranayake H, Lehtolainen-Dalkilic P, Vuorio T, Määttä AM, Wirth T, Airenne KJ, Ylä-Herttuala S.

Hum Gene Ther. 2009 Aug;20(8):871-82. doi: 10.1089/hum.2009.007.

PMID:
19419273
9.

Cloning and characterization of Scavidin, a fusion protein for the targeted delivery of biotinylated molecules.

Lehtolainen P, Taskinen A, Laukkanen J, Airenne KJ, Heino S, Lappalainen M, Ojala K, Marjomäki V, Martin JF, Kulomaa MS, Ylä-Herttuala S.

J Biol Chem. 2002 Mar 8;277(10):8545-50. Epub 2001 Dec 12.

10.

Targeting of vaccinia virus using biotin-avidin viral coating and biotinylated antibodies.

Purow B, Staveley-O'Carroll K.

J Surg Res. 2005 Jan;123(1):49-54.

PMID:
15652950
11.

Introduction of histidine residues into avidin subunit interfaces allows pH-dependent regulation of quaternary structure and biotin binding.

Nordlund HR, Hytönen VP, Laitinen OH, Uotila ST, Niskanen EA, Savolainen J, Porkka E, Kulomaa MS.

FEBS Lett. 2003 Dec 18;555(3):449-54.

12.

Avidin-biotin interaction mediated peptide assemblies as efficient gene delivery vectors for cancer therapy.

Qu W, Chen WH, Kuang Y, Zeng X, Cheng SX, Zhou X, Zhuo RX, Zhang XZ.

Mol Pharm. 2013 Jan 7;10(1):261-9. doi: 10.1021/mp300392z. Epub 2012 Nov 27.

PMID:
23146022
13.
14.

Switchavidin: reversible biotin-avidin-biotin bridges with high affinity and specificity.

Taskinen B, Zauner D, Lehtonen SI, Koskinen M, Thomson C, Kähkönen N, Kukkurainen S, Määttä JA, Ihalainen TO, Kulomaa MS, Gruber HJ, Hytönen VP.

Bioconjug Chem. 2014 Dec 17;25(12):2233-43. doi: 10.1021/bc500462w. Epub 2014 Dec 1.

PMID:
25405260
15.

In vitro targeting of avidin-expressing glioma cells with biotinylated persistent luminescence nanoparticles.

Maldiney T, Kaikkonen MU, Seguin J, le Masne de Chermont Q, Bessodes M, Airenne KJ, Ylä-Herttuala S, Scherman D, Richard C.

Bioconjug Chem. 2012 Mar 21;23(3):472-8. doi: 10.1021/bc200510z. Epub 2012 Feb 7.

PMID:
22250884
16.

Targeted delivery via avidin fusion protein: intracellular fate of biotinylated doxorubicin derivative and cellular uptake kinetics and biodistribution of biotinylated liposomes.

Soininen SK, Lehtolainen-Dalkilic P, Karppinen T, Puustinen T, Dragneva G, Kaikkonen MU, Jauhiainen M, Allart B, Selwood DL, Wirth T, Lesch HP, Määttä AM, Mönkkönen J, Ylä-Herttuala S, Ruponen M.

Eur J Pharm Sci. 2012 Dec 18;47(5):848-56. doi: 10.1016/j.ejps.2012.09.001. Epub 2012 Sep 14.

PMID:
22985874
17.

Conditional expression of Lodavin, an avidin-tagged LDL receptor, for biotin-mediated applications in vivo.

Murugan S, Saarela U, Airenne K, Shan J, Skovorodkin I, Ylä-Herttuala S, Vainio SJ.

Genesis. 2012 Sep;50(9):693-9. doi: 10.1002/dvg.22028. Epub 2012 Apr 24.

PMID:
22467513
18.

Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification.

Parrott MB, Adams KE, Mercier GT, Mok H, Campos SK, Barry MA.

Mol Ther. 2003 Oct;8(4):688-700.

19.

Avidin-biotin technology in targeted therapy.

Lesch HP, Kaikkonen MU, Pikkarainen JT, Ylä-Herttuala S.

Expert Opin Drug Deliv. 2010 May;7(5):551-64. doi: 10.1517/17425241003677749. Review.

PMID:
20233034
20.

Specific binding of baculoviruses displaying gp64 fusion proteins to mammalian cells.

Ojala K, Mottershead DG, Suokko A, Oker-Blom C.

Biochem Biophys Res Commun. 2001 Jun 15;284(3):777-84.

PMID:
11396970

Supplemental Content

Support Center